Theravance, Inc is now called Innoviva.
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com.
Company Details
- Employees
- 6
- Address
- 951 Gateway Blvd, South San Francisco,ca 94080,united States
- Industry
- Investment Management
- NAICS
-
Other Financial Investment ActivitiesPortfolio ManagementAll Other Financial Investment ActivitiesTrust, Fiduciary, and Custody ActivitiesMiscellaneous Financial Investment Activities
- Website
- http://www.thrxinc.com
- Keywords
- in the development.
- HQ
- South San Francisco, CA
Theravance, Inc Questions
Theravance, Inc's website is http://www.thrxinc.com
Theravance, Inc's LinkedIn profile is https://www.linkedin.com/company/theravance-inc
Theravance, Inc has
6 employees.
View email and phone details for 6
employees at Theravance, Inc.
Theravance, Inc's industry is
Investment Management
Theravance, Inc's top competitors are
Acerta Pharma B.v. (A Member Of The Astrazeneca Group),
Cytomx Therapeutics,
Gritstone Technologies,
Spruce Biosciences,
Maze Therapeutics,
Karius,
Vaxart, Inc.,
Theravance Biopharma Us, Llc,
Pliant Therapeutics,
Fibrogen, Inc..
Theravance, Inc's categories are Investment Management
